Emergent signs 5-year deal to make drug used in J&J's Covid-19 vaccine

Emergent BioSolutions Inc said on Monday it signed a five-year contract to make the drug substance used in Johnson & Johnson's Covid-19 vaccine candidate, adding to a series of deals likely to put it at the heart of future global vaccine production.

Under the deal, starting next year Emergent will provide large-scale manufacturing services to produce the drug substance over five years, with the first two years valued at about $480 million. The news follows a $135 million deal struck by the two companies in April, to use Emergent's.....

This article is no longer available in our repository.

There could be multiple reasons for this.